Blackstone Life Sciences is a private equity segment of The Blackstone Group.
Blackstone Life Sciences (BXLS) fills a critical void in the industry. While life sciences is seeing unprecedented innovation driven by rapid advancements in science and technology, it often lacks the necessary funding to bring medicines and healthcare technologies to market. We work in partnership with the pharmaceutical, biotechnology and medical technology industries to help meet this need.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Mar 15, 2022
Sanofi
|
Post-IPO Equity | €300M | Health Care | Yes |
Jun 15, 2020
Medtronic
|
Post-IPO Equity | $337M | Biotechnology | Yes |